SCHEMBL901635

SCHEMBL901635

CC(=O)c1nc2ccnn2c(O)c1Cc1cccc(F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
HPGD P15428 1/20 0.43
MAPK1 P28482 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSD17B10 Q99714 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ENPP1 P22413 1/20 0.40
HCAR2 Q8TDS4 1/20 0.39
MAOB P27338 4/20 0.37
MAOA P21397 1/20 0.37
SCD O00767 1/20 0.36
SCD5 Q86SK9 1/20 0.36
IDH1 O75874 1/20 0.36
GFER P55789 1/20 0.35
LMNA P02545 1/20 0.35
NR3C2 P08235 1/20 0.35
KDM5A P29375 1/20 0.35
KDM5B Q9UGL1 1/20 0.35
PRNP P04156 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL902011 0.90 HCAR2 (0.44) KDM4EALDH1A1HPGDMAPK1SMN1; SMN2
SCHEMBL902640 0.88 ALDH1A1 (0.52) KDM4EALDH1A1HPGDMAPK1SMN1; SMN2
SCHEMBL902261 0.86 PDE4A (0.49) KDM4EALDH1A1HPGDMAPK1SMN1; SMN2
SCHEMBL902320 0.85 L3MBTL1 (0.43) KDM4EALDH1A1HPGDMAPK1SMN1; SMN2
SCHEMBL901506 0.82 RNASEH1 (0.38) KDM5AKDM5B
SCHEMBL902942 0.81 ENPP1 (0.41) KDM4EALDH1A1HPGDMAPK1SMN1; SMN2
SCHEMBL902226 0.80 ENPP1 (0.40) KDM4EALDH1A1HPGDMAPK1SMN1; SMN2
SCHEMBL902417 0.80 ENPP1 (0.40) KDM4EALDH1A1HPGDMAPK1SMN1; SMN2
SCHEMBL902760 0.77 KCNN3 (0.46) KDM4EALDH1A1HPGDMAPK1HSD17B10
SCHEMBL902370 0.77 KCNN3 (0.47) NR3C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
EP-2621928-A1 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS Proximagen Limited (GB) 2013-08-07 EP disclosed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO disclosed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS CCR2, CCR5, CCR1 KDM4E 4265/4885ALDH1A1 441/4885HPGD 670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.